Phase III FLAIR study of cabotegravir + rilpivirine shows efficacy in HIV.- ViiV Healthcare
Related news and insights
Gilead Sciences, Inc. announced new, long-term data from open-label extensions (OLE) of two Phase III studies (Study 1489 and Study 1490) of Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF), demonstrating the sustained efficacy and safety profile and no treatment-emergent resistance with Biktarvy for the treatment of HIV-1 in treatment-naïve adults.
ViiV Healthcare presented positive long-term data from its global phase IIIb ATLAS-2M study of the first complete, long-acting regimen of Cabenuva + Edurant (cabotegravir and rilpivirine) for the treatment of HIV.
ViiV Healthcare, owned by GlaxoSmithKline, announced the European Marketing Authorisation of Rukobia (fostemsavir) 600mg extended-release tablets, for use in combination with other antiretroviral (ARV) therapies for the treatment of adults with multidrug-resistant HIV-1 infection, for whom it is otherwise not possible to construct a suppressive anti-viral regimen.